Cargando…
An evaluation of prescribing trends and patterns of claims within the Preferred Drugs Initiative in Ireland (2011–2016): an interrupted time-series study
OBJECTIVE: To examine the impact of the Preferred Drugs Initiative (PDI), an Irish health policy aimed at enhancing evidence-based cost-effective prescribing, on prescribing trends and the cost of prescription medicines across seven medication classes. DESIGN: Retrospective repeated cross-sectional...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914712/ https://www.ncbi.nlm.nih.gov/pubmed/29678966 http://dx.doi.org/10.1136/bmjopen-2017-019315 |
_version_ | 1783316746894049280 |
---|---|
author | McDowell, Ronald Bennett, Kathleen Moriarty, Frank Clarke, Sarah Barry, Michael Fahey, Tom |
author_facet | McDowell, Ronald Bennett, Kathleen Moriarty, Frank Clarke, Sarah Barry, Michael Fahey, Tom |
author_sort | McDowell, Ronald |
collection | PubMed |
description | OBJECTIVE: To examine the impact of the Preferred Drugs Initiative (PDI), an Irish health policy aimed at enhancing evidence-based cost-effective prescribing, on prescribing trends and the cost of prescription medicines across seven medication classes. DESIGN: Retrospective repeated cross-sectional study spanning the years 2011–2016. SETTING: Health Service Executive Primary Care Reimbursement Service pharmacy claims data for General Medical Services (GMS) patients, approximately 40% of the Irish population. PARTICIPANTS: Adults aged ≥18 years between 2011 and 2016 are eligible for the GMS scheme. PRIMARY AND SECONDARY OUTCOMES: The percentage of PDI medications within each drug class per calendar quarter. Linear regression was used to model prescribing of the preferred drug within each medication group and to assess the impact of PDI guidelines and other relevant changes in prescribing practice. Savings in drug expenditure were estimated. RESULTS: Between 2011 and 2016, around a quarter (23.59%) of all medications were for single-agent drugs licensed in the seven drug classes. There was a small increase in the percentage of PDI drugs, increasing from 4.64% of all medications in 2011 to 4.76% in 2016 (P<0.001). The percentage of preferred drugs within each drug class was significantly higher immediately following publication of the guidelines for all classes except urology, with the largest increases noted for lansoprazole (1.21%, 95% CI: 0.84% to 1.57%, P<0.001) and venlafaxine (0.71%, 95% CI: 0.15% to 1.27%, P=0.02). Trends in prescribing of the preferred drugs between PDI guidelines and the end of 2016 varied between drug classes. Total cost savings between 2013 and 2016 were estimated to be €2.7 million. CONCLUSION: There has been a small increase in prescribing of PDI drugs in response to prescribing guidelines, with inconsistent changes observed across therapeutic classes. These findings are relevant where health services are seeking to develop more active prescribing interventions aimed at changing prescribing practice. |
format | Online Article Text |
id | pubmed-5914712 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-59147122018-04-27 An evaluation of prescribing trends and patterns of claims within the Preferred Drugs Initiative in Ireland (2011–2016): an interrupted time-series study McDowell, Ronald Bennett, Kathleen Moriarty, Frank Clarke, Sarah Barry, Michael Fahey, Tom BMJ Open Epidemiology OBJECTIVE: To examine the impact of the Preferred Drugs Initiative (PDI), an Irish health policy aimed at enhancing evidence-based cost-effective prescribing, on prescribing trends and the cost of prescription medicines across seven medication classes. DESIGN: Retrospective repeated cross-sectional study spanning the years 2011–2016. SETTING: Health Service Executive Primary Care Reimbursement Service pharmacy claims data for General Medical Services (GMS) patients, approximately 40% of the Irish population. PARTICIPANTS: Adults aged ≥18 years between 2011 and 2016 are eligible for the GMS scheme. PRIMARY AND SECONDARY OUTCOMES: The percentage of PDI medications within each drug class per calendar quarter. Linear regression was used to model prescribing of the preferred drug within each medication group and to assess the impact of PDI guidelines and other relevant changes in prescribing practice. Savings in drug expenditure were estimated. RESULTS: Between 2011 and 2016, around a quarter (23.59%) of all medications were for single-agent drugs licensed in the seven drug classes. There was a small increase in the percentage of PDI drugs, increasing from 4.64% of all medications in 2011 to 4.76% in 2016 (P<0.001). The percentage of preferred drugs within each drug class was significantly higher immediately following publication of the guidelines for all classes except urology, with the largest increases noted for lansoprazole (1.21%, 95% CI: 0.84% to 1.57%, P<0.001) and venlafaxine (0.71%, 95% CI: 0.15% to 1.27%, P=0.02). Trends in prescribing of the preferred drugs between PDI guidelines and the end of 2016 varied between drug classes. Total cost savings between 2013 and 2016 were estimated to be €2.7 million. CONCLUSION: There has been a small increase in prescribing of PDI drugs in response to prescribing guidelines, with inconsistent changes observed across therapeutic classes. These findings are relevant where health services are seeking to develop more active prescribing interventions aimed at changing prescribing practice. BMJ Publishing Group 2018-04-20 /pmc/articles/PMC5914712/ /pubmed/29678966 http://dx.doi.org/10.1136/bmjopen-2017-019315 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Epidemiology McDowell, Ronald Bennett, Kathleen Moriarty, Frank Clarke, Sarah Barry, Michael Fahey, Tom An evaluation of prescribing trends and patterns of claims within the Preferred Drugs Initiative in Ireland (2011–2016): an interrupted time-series study |
title | An evaluation of prescribing trends and patterns of claims within the Preferred Drugs Initiative in Ireland (2011–2016): an interrupted time-series study |
title_full | An evaluation of prescribing trends and patterns of claims within the Preferred Drugs Initiative in Ireland (2011–2016): an interrupted time-series study |
title_fullStr | An evaluation of prescribing trends and patterns of claims within the Preferred Drugs Initiative in Ireland (2011–2016): an interrupted time-series study |
title_full_unstemmed | An evaluation of prescribing trends and patterns of claims within the Preferred Drugs Initiative in Ireland (2011–2016): an interrupted time-series study |
title_short | An evaluation of prescribing trends and patterns of claims within the Preferred Drugs Initiative in Ireland (2011–2016): an interrupted time-series study |
title_sort | evaluation of prescribing trends and patterns of claims within the preferred drugs initiative in ireland (2011–2016): an interrupted time-series study |
topic | Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914712/ https://www.ncbi.nlm.nih.gov/pubmed/29678966 http://dx.doi.org/10.1136/bmjopen-2017-019315 |
work_keys_str_mv | AT mcdowellronald anevaluationofprescribingtrendsandpatternsofclaimswithinthepreferreddrugsinitiativeinireland20112016aninterruptedtimeseriesstudy AT bennettkathleen anevaluationofprescribingtrendsandpatternsofclaimswithinthepreferreddrugsinitiativeinireland20112016aninterruptedtimeseriesstudy AT moriartyfrank anevaluationofprescribingtrendsandpatternsofclaimswithinthepreferreddrugsinitiativeinireland20112016aninterruptedtimeseriesstudy AT clarkesarah anevaluationofprescribingtrendsandpatternsofclaimswithinthepreferreddrugsinitiativeinireland20112016aninterruptedtimeseriesstudy AT barrymichael anevaluationofprescribingtrendsandpatternsofclaimswithinthepreferreddrugsinitiativeinireland20112016aninterruptedtimeseriesstudy AT faheytom anevaluationofprescribingtrendsandpatternsofclaimswithinthepreferreddrugsinitiativeinireland20112016aninterruptedtimeseriesstudy AT mcdowellronald evaluationofprescribingtrendsandpatternsofclaimswithinthepreferreddrugsinitiativeinireland20112016aninterruptedtimeseriesstudy AT bennettkathleen evaluationofprescribingtrendsandpatternsofclaimswithinthepreferreddrugsinitiativeinireland20112016aninterruptedtimeseriesstudy AT moriartyfrank evaluationofprescribingtrendsandpatternsofclaimswithinthepreferreddrugsinitiativeinireland20112016aninterruptedtimeseriesstudy AT clarkesarah evaluationofprescribingtrendsandpatternsofclaimswithinthepreferreddrugsinitiativeinireland20112016aninterruptedtimeseriesstudy AT barrymichael evaluationofprescribingtrendsandpatternsofclaimswithinthepreferreddrugsinitiativeinireland20112016aninterruptedtimeseriesstudy AT faheytom evaluationofprescribingtrendsandpatternsofclaimswithinthepreferreddrugsinitiativeinireland20112016aninterruptedtimeseriesstudy |